---
schema_version: "secwatch.filing_event.v1"
accession: "0001472375-23-000134"
form_type: "8-K"
ticker: "RGPX"
cik: "0001357878"
company_name: "REGENEREX PHARMA, INC."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:31:23.644571+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans

## Summary
- Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.
- Claims 95% of chronic wounds show 100% closure within 90 days in clinical evaluations.
- Manufacturing to begin in Q4 2023 at facility in Memphis, TN.
- No specific management officer or director names were provided in the update.
- Products are FDA-cleared or OTC; Accelerex is a prescription-only combination device.

## SEC filing metadata
- accession: 0001472375-23-000134
- form_type: 8-K
- ticker: RGPX
- cik: 0001357878
- company_name: REGENEREX PHARMA, INC.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/0001472375-23-000134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/ixform8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001472375-23-000134
- JSON: https://secwatch.observer/filing/0001472375-23-000134.json
- Plain text: https://secwatch.observer/filing/0001472375-23-000134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.